Guided Therapeutics (GTHP) Debt to Equity (2016 - 2025)
Guided Therapeutics (GTHP) has disclosed Debt to Equity for 14 consecutive years, with -$0.01 as the latest value for Q4 2025.
- Quarterly Debt to Equity rose 70.37% to -$0.01 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.01 through Dec 2025, up 70.37% year-over-year, with the annual reading at -$0.01 for FY2025, 70.37% up from the prior year.
- Debt to Equity hit -$0.01 in Q4 2025 for Guided Therapeutics, up from -$0.02 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of -$0.01 in Q1 2021 to a low of -$0.25 in Q2 2024.
- Historically, Debt to Equity has averaged -$0.07 across 4 years, with a median of -$0.02 in 2022.
- Biggest five-year swings in Debt to Equity: crashed 3545.45% in 2021 and later surged 93.19% in 2025.
- Year by year, Debt to Equity stood at -$0.02 in 2021, then crashed by 71.7% to -$0.03 in 2022, then rose by 2.7% to -$0.03 in 2024, then soared by 70.37% to -$0.01 in 2025.
- Business Quant data shows Debt to Equity for GTHP at -$0.01 in Q4 2025, -$0.02 in Q3 2025, and -$0.02 in Q2 2025.